Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

We conducted a randomized, controlled trial in 72 patients with heterozygous familial hypercholesterolemia to test whether reducing plasma low-density lipoprotein levels by diet and combined drug regimens can induce regression of coronary lesions. Four hundred fifty-seven lesions were measured before and after a 26-month interval by computer-based quantitative angiography. The primary outcome variable was within-patient mean change in percent area stenosis. Mean low-density lipoprotein cholesterol levels decreased from 7.32 +/- 1.5 to 4.45 +/- 1.6 mmol/L. The mean change in percent area stenosis among controls was +0.80, indicating progression, while the mean change for the treatment group was -1.53, indicating regression (P = .039 by two-tailed t test for the difference between groups). Regression among women, analyzed separately, was also significant. The change in percent area stenosis was correlated with low-density lipoprotein levels on trial. We conclude that reduction of low-density lipoprotein cholesterol levels can induce regression of atherosclerotic lesions of the coronary arteries in patients with familial hypercholesterolemia. The anticipation of benefit from treatment applies to women and men alike.

[1]  R. Havel,et al.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. , 1977, Journal of lipid research.

[2]  E. Bolson,et al.  Quantitative Coronary Arteriography: Estimation of Dimensions, Hemodynamic Resistance, and Atheroma Mass of Coronary Artery Lesions Using the Arteriogram and Digital Computation , 1977, Circulation.

[3]  E L Bolson,et al.  Quantitative computer techniques for analyzing coronary arteriograms. , 1986, Progress in cardiovascular diseases.

[4]  J. Huttunen,et al.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.

[5]  Myers Lh,et al.  Mathematical evaluation of methods for estimation of the concentration of the major lipid components of human serum lipoproteins. , 1976 .

[6]  M. Armstrong,et al.  Regression of Coronary Atheromatosis in Rhesus Monkeys , 1970, Circulation research.

[7]  M. Bond,et al.  A study of atherosclerosis regression in Macaca mulatta. IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. , 1981, Experimental and molecular pathology.

[8]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[9]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[10]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[11]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[12]  M. Malloy,et al.  Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. , 1987, Annals of internal medicine.

[13]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[14]  M. Fisher,et al.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. , 1984, Circulation.

[15]  M J Malloy,et al.  Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. , 1981, The New England journal of medicine.